United Therapeutics is escalating its patent dispute over a high blood pressure drug, requesting the intervention of the U.S. Supreme Court. This legal showdown aims to prevent a rival company from marketing a competing treatment to United Therapeutics’ high-revenue medication. The patent case underscores the ongoing high-stakes battles within the pharmaceutical industry, particularly over lucrative treatments for chronic conditions. For more detailed information, the full context of the case can be accessed here.